87 research outputs found
Co-morbidity burden in Parkinsonās disease : Comparison with controls and its influence on prognosis
Financial support This study was funded by Parkinsonās UK, the Scottish Chief Scientist Office, NHS Grampian endowments, the BMA Doris Hillier award, RS Macdonald Trust, the BUPA Foundation, and SPRING. The funders had no involvement in the study. Acknowledgements We acknowledge funding for the PINE study from Parkinsonās UK (G-0502, G-0914, G-1302), the Scottish Chief Scientist Office(CAF/12/05), the BMA Doris Hillier award, RS Macdonald Trust, the BUPA Foundation, NHS Grampian endowments and SPRING. We thank the patients and controls for their participation and the research staff who collected data and supported the study database.Peer reviewedPostprintPostprintPublisher PD
Incidence and risk factors of institutionalisation in Parkinson's disease and atypical parkinsonism
Open Access via the Elsevier Agreement We would like to thank the patients for their participation and the research staff who collected data and supported the study database. The PINE study was funded by Parkinson's UK (grant numbers G0502, G0914, and G1302), the Scottish Chief Scientist Office (CAF/12/05, PCL/17/10), NHS Grampian endowments, the BMA Doris Hillier award, RS Macdonald Trust, the BUPA Foundation and SPRING. Yan Li is funded by a studentship from the Meikle Foundation.Peer reviewedPublisher PD
Examining outcomes following thrombolysis in an increasingly older and dependent stroke population
We are grateful for the support of the nurses from Chest, Heart and Stroke Scotland for assisting in obtaining follow-up functional status at three months.Peer reviewedPublisher PD
Reversible tongue atrophy in Lambert-Eaton myasthenic syndrome
Peer reviewedPublisher PD
Impaired value-based decision-making in Parkinsonās Disease Apathy
Apathy is a common and disabling complication of Parkinsonās disease characterized by reduced goal-directed behaviour. Several studies have reported dysfunction within prefrontal cortical regions and projections from brainstem nuclei whose neuromodulators include dopamine, serotonin and noradrenaline. Work in animal and human neuroscience have confirmed contributions of these neuromodulators on aspects of motivated decision-making. Specifically, these neuromodulators have overlapping contributions to encoding the value of decisions, and influence whether to explore alternative courses of action or persist in an existing strategy to achieve a rewarding goal. Building upon this work, we hypothesized that apathy in Parkinsonās disease should be associated with an impairment in value-based learning. Using a four-armed restless bandit reinforcement learning task, we studied decision-making in 75 volunteers; 53 patients with Parkinsonās disease, with and without clinical apathy, and 22 age-matched healthy control subjects. Patients with apathy exhibited impaired ability to choose the highest value bandit. Task performance predicted an individual patientās apathy severity measured using the Lille Apathy Rating Scale (R = ā0.46, P < 0.001). Computational modelling of the patientās choices confirmed the apathy group made decisions that were indifferent to the learnt value of the options, consistent with previous reports of reward insensitivity. Further analysis demonstrated a shift away from exploiting the highest value option and a reduction in perseveration, which also correlated with apathy scores (R = ā0.5, P < 0.001). We went on to acquire functional MRI in 59 volunteers; a group of 19 patients with and 20 without apathy and 20 age-matched controls performing the Restless Bandit Task. Analysis of the functional MRI signal at the point of reward feedback confirmed diminished signal within ventromedial prefrontal cortex in Parkinsonās disease, which was more marked in apathy, but not predictive of their individual apathy severity. Using a model-based categorization of choice type, decisions to explore lower value bandits in the apathy group activated prefrontal cortex to a similar degree to the age-matched controls. In contrast, Parkinsonās patients without apathy demonstrated significantly increased activation across a distributed thalamo-cortical network. Enhanced activity in the thalamus predicted individual apathy severity across both patient groups and exhibited functional connectivity with dorsal anterior cingulate cortex and anterior insula. Given that task performance in patients without apathy was no different to the age-matched control subjects, we interpret the recruitment of this network as a possible compensatory mechanism, which compensates against symptomatic manifestation of apathy in Parkinsonās disease.</p
Age-related selection bias in Parkinson's disease research : are we recruiting the right participants?
Acknowledgements We acknowledge the earlier work of Dr Kate Taylor and Dr Dominique Twelves on the previous systematic review of incidence studies in Parkinsonās disease. Funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Authors report the following funding received during the conduct of this study: Dr Macleod: fellowship funding from the Chief Scientist Office of the Scottish Government and NHS Education for Scotland; grant funding Parkinsonās UK, the Academy of Medical Sciences, NHS Grampian Endowments, the Wellcome Trust, the University of Aberdeen. Dr Henery: financial support from the University of Aberdeen Dr Nwajiugo: none Dr Scott: none Dr Caslake: grant funding from Parkinsonās UK Dr Counsell: grant funding from the Chief Scientist Office of the Scottish Government, the PSP Association, and NHS Grampian Endowments.Peer reviewedPostprin
Impaired value-based decision-making in Parkinsonās Disease Apathy
Apathy is a common and disabling complication of Parkinsonās disease characterized by reduced goal-directed behaviour. Several studies have reported dysfunction within prefrontal cortical regions and projections from brainstem nuclei whose neuromodulators include dopamine, serotonin and noradrenaline. Work in animal and human neuroscience have confirmed contributions of these neuromodulators on aspects of motivated decision-making. Specifically, these neuromodulators have overlapping contributions to encoding the value of decisions, and influence whether to explore alternative courses of action or persist in an existing strategy to achieve a rewarding goal. Building upon this work, we hypothesized that apathy in Parkinsonās disease should be associated with an impairment in value-based learning. Using a four-armed restless bandit reinforcement learning task, we studied decision-making in 75 volunteers; 53 patients with Parkinsonās disease, with and without clinical apathy, and 22 age-matched healthy control subjects. Patients with apathy exhibited impaired ability to choose the highest value bandit. Task performance predicted an individual patientās apathy severity measured using the Lille Apathy Rating Scale (R = ā0.46, P < 0.001). Computational modelling of the patientās choices confirmed the apathy group made decisions that were indifferent to the learnt value of the options, consistent with previous reports of reward insensitivity. Further analysis demonstrated a shift away from exploiting the highest value option and a reduction in perseveration, which also correlated with apathy scores (R = ā0.5, P < 0.001). We went on to acquire functional MRI in 59 volunteers; a group of 19 patients with and 20 without apathy and 20 age-matched controls performing the Restless Bandit Task. Analysis of the functional MRI signal at the point of reward feedback confirmed diminished signal within ventromedial prefrontal cortex in Parkinsonās disease, which was more marked in apathy, but not predictive of their individual apathy severity. Using a model-based categorization of choice type, decisions to explore lower value bandits in the apathy group activated prefrontal cortex to a similar degree to the age-matched controls. In contrast, Parkinsonās patients without apathy demonstrated significantly increased activation across a distributed thalamo-cortical network. Enhanced activity in the thalamus predicted individual apathy severity across both patient groups and exhibited functional connectivity with dorsal anterior cingulate cortex and anterior insula. Given that task performance in patients without apathy was no different to the age-matched control subjects, we interpret the recruitment of this network as a possible compensatory mechanism, which compensates against symptomatic manifestation of apathy in Parkinsonās disease.</p
Lack of Association Between GBA Mutations and Motor Complications in European and American Parkinson's Disease Cohorts
ACKNOWLEDGMENTS The authors would like to thank all of the patients and controls for participation in each of the studies. Equally, we thank all members of each of the study groups and other personnel for their contributions. Funding sources for the respective studies are as follows: The Norwegian ParkWest study has been funded by the Research Council of Norway (177966), the Western Norway Regional Health Authority (911218), the Norwegian Parkinsonās Research Foundation, and Rebergs Legacy. PINE study was supported by Parkinsonās UK (G0502, G0914, G1302), Scottish Government Chief Scientist Office, BMA Doris Hillier Award, the BUPA Foundation, NHS Grampian Endowments, and RS MacDonald Trust. The NYPUM study has been funded by the Swedish Medical Research Council, the Swedish Parkinsonās disease Association, the Swedish Parkinsonās Foundation, Parkinson Research Foundation, Erling Persson Foundation, Kempe Foundation, the Swedish Brain Foundation (Hjarnfonden), and the Vasterbotten County Council. AAS, JMG and GA are supported by the Research Council of Norway (287842). BLF acknowledges support through donations to the UCLA Clinical Neurogenomics Research Center. CK is supported by the NIH grant F32AG063442. The PEG study was supported by NIH/NIEHS grants R01-ES010544 and U54-ES012078. Publication of this manuscript was supported under the The Michael J. Fox Foundation: 2021 RFA: Accelerating Publication of Parkinsonās Disease Replication Data.Peer reviewedPublisher PD
Validation of a UPDRS-/MDS-UPDRS-based definition of functional dependency for Parkinson's disease
Copyright Ā© 2020. Published by Elsevier Ltd.Peer reviewedPostprin
Lack of Association Between GBA Mutations and Motor Complications in European and American Parkinson's Disease Cohorts
Background:
Motor complications are a consequence of the chronic dopaminergic treatment of Parkinsonās disease (PD) and include levodopa-induced dyskinesia (LIDs) and motor fluctuations (MF). Currently, evidence is on lacking whether patients with GBA-associated PD differ in their risk of developing motor complications compared to the general PD population.
Objective:
To evaluate the association of GBA carrier status with the development of LIDS and MFs from early PD.
Methods:
Motor complications were recorded prospectively in 884 patients with PD from four longitudinal cohorts using part IV of the UPDRS or MDS-UPDRS. Subjects were followed for up to 11 years and the associations of GBA mutations with the development of motor complications were assessed using parametric accelerated failure time models.
Results:
In 439 patients from Europe, GBA mutations were detected in 53 (12.1%) patients and a total of 168 cases of LIDs and 258 cases of MF were observed. GBA carrier status was not associated with the time to develop LIDs (HR 0.78, 95%CI 0.47 to 1.26, pā=ā0.30) or MF (HR 1.19, 95%CI 0.84 to 1.70, pā=ā0.33). In the American cohorts, GBA mutations were detected in 36 (8.1%) patients and GBA carrier status was also not associated with the progression to LIDs (HR 1.08, 95%CI 0.55 to 2.14, pā=ā0.82) or MF (HR 1.22, 95%CI 0.74 to 2.04, pā=ā0.43).
Conclusion:
This study does not provide evidence that GBA-carrier status is associated with a higher risk of developing motor complications. Publication of studies with null results is vital to develop an accurate summary of the clinical features that impact patients with GBA-associated PD.publishedVersio
- ā¦